The test identifies the SARS-CoV-2 nucleocapsid protein antigen in 15 minutes. Credit: Sapphiros/PRNewswire.

Consumer diagnostics platform company Sapphiros has signed a Covid-19 test distribution agreement with Cencora, which was formerly known as AmerisourceBergen Corporation.

Under the deal, Cencora will be responsible for distributing the Sapphiros’s GoToKnow Covid-19 Antigen Rapid Tests to pharmacies in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sapphiros expects the strategic partnership to improve accessibility and convenience for patients looking to purchase reliable Covid-19 testing solutions.

Authorised by the US Food and Drug Administration only for the detection of proteins from SARS-CoV-2, the GoToKnow rapid antigen test is developed to allow users to take tests at home.

It provides results in 15 minutes for the identification of the SARS-CoV-2 nucleocapsid protein antigen.

See Also:

During the acute infection phase, this antigen is generally detectable in anterior nasal swab specimens.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cencora will also have access to Sapphiros’s future technologies, including additional rapid lateral flow tests for diseases beyond Covid-19, a fully disposable, low-cost multiplexed molecular diagnostics platform, and the Satio blood collection patch planned to be launched early next year.

Sapphiros CEO Mark Gladwell said: “This is a significant milestone for our company and further validates Sapphiros’s unique and transformational technologies.

“We are honoured to partner with Cencora to bring this product as well as future innovative product offerings directly to patients across the US enabling the consumer to directly access their diagnostic results and manage their health.”

Backed by KKR and Neoenta, Sapphiros has a portfolio of capabilities and technologies such as novel sample collection, next-generation diagnostics, computational biology, and printed electronics.